1,437 reports of this reaction
5.8% of all PALIVIZUMAB reports
#2 most reported adverse reaction
PYREXIA is the #2 most commonly reported adverse reaction for PALIVIZUMAB, manufactured by Swedish Orphan Biovitrum AB (publ). There are 1,437 FDA adverse event reports linking PALIVIZUMAB to PYREXIA. This represents approximately 5.8% of all 24,586 adverse event reports for this drug.
Patients taking PALIVIZUMAB who experience pyrexia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PYREXIA is moderately reported among PALIVIZUMAB users, representing a notable but not dominant share of adverse events.
In addition to pyrexia, the following adverse reactions have been reported for PALIVIZUMAB:
The following drugs have also been linked to pyrexia in FDA adverse event reports:
PYREXIA has been reported as an adverse event in 1,437 FDA reports for PALIVIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
PYREXIA accounts for approximately 5.8% of all adverse event reports for PALIVIZUMAB, making it one of the most commonly reported side effect.
If you experience pyrexia while taking PALIVIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.